What is the difference between ARA-290 and Foxo4-DRI?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing Foxo4-DRI: D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Foxo4-DRI FDA approved?

Foxo4-DRI is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Foxo4-DRI administered in research settings?

In research settings, Foxo4-DRI is typically administered via the intravenous or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs Foxo4-DRI

Peptide Comparison

ARA-290 vs Foxo4-DRI

Name: ARA-290 vs Foxo4-DRI — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

16 providers listed

Full ARA-290 profile →

Foxo4-DRI

Foxo4-D-Retro-Inverso

LongevityNot EvaluatedResearch Only

Half-life: Unknown

13 providers listed

Full Foxo4-DRI profile →

Bottom line

ARA-290 carries stronger published evidence (RCT, 3 key studies) than Foxo4-DRI (Review, 3); both are research compounds.

Quick Verdict

ARA-290

Evidence

Clinical

Half-life

~2 min (IV); ~10–20 min (SC)

Foxo4-DRI

Evidence

Preclinical

Half-life

Unknown

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ARA-290
Further along in FDA review	ARA-290
Lower typical price per mg	ARA-290
More provider options (16 vs 13)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

Foxo4-DRI

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

Unknown

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

intravenous, subcutaneous

Availability

Research Only

Providers

16 listed

13 listed

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

Senolytic D-retro-inverso Foxo4 peptide (de Keizer lab, Netherlands). Eliminates p21-positive senescent cells. No FDA approval, no IND or NDA. Novel research compound only.

Research Evidence

ARA-290

ClinicalRCT · 3 key studies · most recent 2026

Foxo4-DRI

PreclinicalReview · 3 key studies · most recent 2026

Research Citations

ARA-290

Cohort2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

RCT2015 · Molecular Medicine

ARA 290, a non-hematopoietic erythropoietin analogue, improves metabolic control and neuropathic symptoms in…

Foxo4-DRI

Animal2017 · Cell

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Review2026 · Naunyn Schmiedebergs Arch Pharmacol

Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigat…

Animal2021 · EBioMedicine

Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-…

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Foxo4-DRI

D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

Research Areas

senescent cell clearancetissue rejuvenationhealthspan extensionsenolytic

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Foxo4-DRI

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

ARA-290

$5.00/mg

$4.00 – $5.42 range

17 vendors

View price index →Find providers →

Foxo4-DRI

$22.00/mg

$20.00 – $27.00 range

5 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ARA-290

16 listed

Browse directory →

Providers offering

Foxo4-DRI

13 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Foxo4-DRI — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/ara-290/foxo4-dri

https://peptidebase.io/peptides/compare/ara-290/foxo4-dri Methodology License Download JSON Download CSV